Home - Abecma Rems
Time 2022-10-12 15:30:46Web Name: Home - Abecma Rems
WebSite: http://www.abecmarems.com
ID:349775
Keywords:
Home,Abecma,RemsDescription:
Risk Evaluation and Mitigation Strategy (REMS)
Boxed Warning
CYTOKINE RELEASE SYNDROME, NEUROLOGIC TOXICITIES, HLH/MAS, AND PROLONGEDCYTOPENIA
Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients following treatment with ABECMA. Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab andcorticosteroids.
Neurologic toxicities, which may be severe or life-threatening, occurred following treatment with ABECMA, including concurrently with CRS, after CRS resolution, or in the absence of CRS. Monitor for neurologic events after treatment with ABECMA. Provide supportive care and/or corticosteroids asneeded.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including fatal and life-threatening reactions, occurred in patients following treatment with ABECMA. HLH/MAS can occur with CRS or neurologictoxicities.
Prolonged Cytopenia with bleeding and infection, including fatal outcomes following stem cell transplantation for hematopoietic recovery, occurred following treatment withABECMA.
ABECMA is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the ABECMAREMS.
About ABECMA REMS
A REMS is a drug safety program to manage known or potential risks associated with a drug and is required by the United States (US) Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks. ABECMA is only available under a restricted program called ABECMA REMS because of the serious risks of CRS and neurologic toxicities.
The goals of ABECMA REMS are to mitigate the risks of CRS and neurologic toxicities by:
Ensuring that hospitals and their associated clinic(s) that dispense ABECMA are specially certified and have on-site immediate access to tocilizumab.
Ensuring that those who prescribe, dispense, or administer ABECMA are aware of how to manage the risks of CRS and neurologic toxicities.
ABECMA REMS Requirements
All hospitals and their associated clinic(s) must be certified and enrolled in the ABECMA REMS to be able to dispense ABECMA.
All relevant staff involved in the prescribing, dispensing, or administering of ABECMA are trained on ABECMA REMS requirements, and must successfully complete the Knowledge Assessment and submit it to the REMS Program.
Hospital and Associated Clinic Enrollment Instructions
To become certified to dispense ABECMA, hospitals and their associated clinic(s) must designate an authorized representative (AR) to complete REMS requirements and enroll in ABECMA REMS. The AR must:
Complete the ABECMA REMS Training Program (live in-person, via webcast, or online), which includes review of:
REMS Training ProgramREMS Adverse Reaction Management GuideSuccessfully complete the Knowledge Assessment and submit it to the REMSProgram.
Oversee implementation and compliance with ABECMA REMS requirements to:
Ensure that all relevant staff involved in prescribing, dispensing, or administering of ABECMA are trained on the REMS requirements using the Training Program, and successfully complete and submit the Knowledge Assessment, and records are maintained of staff training.
Put processes and procedures in place to ensure that staff involved in the prescribing, dispensing, or administering of ABECMA are retrained on ABECMA REMS if ABECMA has not been dispensed at least once annually from the date of certification in the ABECMA REMS.
Prior to infusing ABECMA, put processes and procedures in place to verify a minimum of 2 doses of tocilizumab are available on-site for each patient and are ready for immediate administration (within 2 hours).
Prior to infusing ABECMA, provide patients with the Patient Wallet Card and instruct patients to remain within 2 hours of the certified healthcare facility for at least 4 weeks following ABECMA infusion.
Ensure that when the hospital and its associated clinic(s) designate an AR, the AR must complete the Training Program, successfully complete the Knowledge Assessment, and complete and submit a new Hospital Enrollment Form.
Submit a completed Hospital Enrollment Form.
Report suspected adverse reactions to Celgene Corporation, a Bristol-Myers Squibb Company, at www.bms.com or 1-888-805-4555 or to the FDA at www.fda.gov/medwatch or by calling 1-800-FDA-1088.
Indication
ABECMA is a B-cell maturation antigen (BCMA)-directed genetically modified autologous Tcell immunotherapy indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
CONTACT
For more information about ABECMAREMS, call 1-888-423-5436.
RESOURCES
ABECMA Prescribing Information
ABECMA Medication Guide
ABECMA REMS Knowledge Assessment
ABECMA REMS TrainingProgram
ABECMA REMS Patient Wallet Card
ABECMA REMS Adverse Reaction Management Guide
ABECMA® online REMS training and Knowledge Assessment is currently unavailable. The ABECMA REMS Training Program and Knowledge Assessment is available for download in the Resources Section at www.AbecmaREMS.com. Please contact the REMS Call Center with any questions at 1-888-423-5436.
<<< Thank you for your visit >>>
Websites to related : Homepage | SW-Stahl GmbH
Hudson Ridge | Townhomes in Red
Phone Number (833) 751-2059
Meadow Springs | Townhome in HanPhone Number (833) 292-3805
Gettysburg Ridge | Townhomes inPhone Number (833) 242-1821
East Walnut Street | Townhomes iPhone Number (833) 537-6304
Home - California Retailer's AssSkip to contentMain MenuWho We AreWhy You Should JoinAdvocacyContactResourcesCal ORCAEventsNewsAssociate MembershipsCRA LeadershipCRA CommitteesAuror
Home - Grosslight InsuranceHomeAboutCoverageServicesContact UsGet a QuoteLife InsuranceHomeAboutCoverageServicesContact UsGet a QuoteLife InsuranceTrusted Advisors to mi
Stormfitters Joins the West ShorSkip to content Join the Mission to Conquer Childhood Cancer. Learn More
Home - PulaWHO WE ARETeamCase StudiesPRODUCTS AND SERVICESInsuranceCrop InsuranceLivestock InsuranceField SenseJOIN OUR TEAMBLOGCONTACT USSelect Page Global I
Soins à domicile Lausanne - HomACCUEILÀ PROPOSPRESTATIONSMÉDICALSERVICESACCOMPAGNEMENT EN FIN DE VIETARIFS ET INFORMATIONSDÉMARCHESACTUALITÉSBLOGMÉDIASCARRIÈRECONTACTSélectio
adsHot Websites